抗精神病薬の世界市場 - 2025年～2032年

世界の抗精神病薬市場は、2024年に164億1,000万米ドルに達し、2032年には328億3,000万米ドルに達すると予測され、予測期間2025年のCAGRは7.9％で成長します。

抗精神病薬は、妄想、幻覚、思考の混乱などの症状を含む精神病を管理するために処方される重要な精神医薬品のクラスです。抗精神病薬は主に、統合失調症、双極性障害、重度のうつ病などの治療に使用されます。

抗精神病薬はさまざまな形で投与されます。最も一般的な方法は錠剤や液剤による経口摂取です。さらに、一部の抗精神病薬はデポ注射として利用可能であり、数週間ごとに投与することで、徐放性で長時間作用する治療の選択肢となります。

抗精神病薬は精神病症状の緩和と気分の安定に効果的であり、個人の症状をより効果的に管理し、日常生活の機能改善を可能にします。抗精神病薬の開発は、その有効性と安全性を高め続けており、現代の精神科医療に欠かせない要素となっています。例えば

市場力学：

促進要因と抑制要因

革新的な抗精神病薬のイントロダクション

革新的な抗精神病薬の導入は、いくつかの説得力のある理由により、抗精神病薬市場を大きく推進すると予想されます。企業は、複数の精神疾患を治療する能力を備えた革新的なソリューションを導入しています。例えば、2023年4月、Teva社とMedinCell社は、成人の統合失調症治療用の長時間作用型皮下非定型抗精神病薬注射剤であるUZEDY（リスペリドン）徐放性注射懸濁液のFDA承認を発表しました。先進的な薬剤、特に第2、第3世代の抗精神病薬は忍容性を高めるように設計されており、これは患者の治療レジメンへのアドヒアランスを確保するために極めて重要であり、その結果、これらの薬剤に対する全体的な需要が増加しています。

さらに、医薬品の研究開発の進歩により、投与回数を減らしながら治療効果を持続させる長時間作用型注射剤のような革新的な製剤や開発方法が生まれています。こうした技術革新は、患者のコンプライアンスを向上させるだけでなく、複雑な精神疾患に対する治療の選択肢を広げます。例えば、ブリストル・マイヤーズスクイブ社は2024年9月、成人の統合失調症治療用の経口薬であるCOBENFY（キサノメリン・塩化トロスピウム）について、米国食品医薬品局（FDA）の承認を取得しました。コベンファイは、D2受容体を阻害することなく、脳内のM1およびM4受容体を選択的に標的とすることで、統合失調症の治療に根本的な新しいアプローチを導入するもので、数十年ぶりの新薬となります。

さらに、精神疾患に対する世界の意識の高まりにより、統合失調症や双極性障害などの治療薬を求める人が増え、効果的な抗精神病薬に対する需要が加速しています。市場の発展に伴い、特定の神経伝達系に焦点を当てた標的療法の出現も、臨床医と患者の双方から大きな関心を集め、市場の成長軌道を強化すると予想されます。

メンタルヘルス疾患に対する認識不足

精神疾患に対する認識不足は、抗精神病薬市場の成長を大きく阻害すると予想されます。統合失調症や双極性障害などの精神疾患を患っている人の多くは、自分の症状を認識していなかったり、治療を受けることの重要性を理解していなかったりすることが多いです。このような認識のギャップは過小診断や過小治療につながり、結果として抗精神病薬治療を必要とする患者数を減少させることになります。その結果、製薬会社は市場へのリーチを広げ、効果的な販売促進に苦戦することになるかもしれないです。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
  • 抑制要因
    • 精神疾患に対する認識の欠如
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 薬の種類別

• 第一世代抗精神病薬
  • リスペリドン
  • クエチアピン
  • オランザピン
  • ジプラシドン
  • パリペリドン
  • クロザピン
  • その他
• 第二世代抗精神病薬
  • クロルプロマジン
  • フルペンチキソール
  • アフルフェナジン
  • ハロペリドール
  • ロキサピン
  • ペルフェナジン
  • ピモジド
  • トリフルオペラジン
  • その他
• 第三世代抗精神病薬
  • アリピプラゾール

第7章 適応症別

• 統合失調症
• 痴呆
• 双極性障害
• うつ
• その他

第8章 投与経路別

• 経口
• 非経口

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第12章 企業プロファイル

• Dr. Reddy's Laboratories Ltd.
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Otsuka Pharmaceutical Co., Ltd.
• Johnson & Johnson Services, Inc.
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Alkermes
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Sumitomo Pharma Co., Ltd.
• Pfizer Inc.

第13章 付録

The global antipsychotic drugs market reached US$ 16.41 billion in 2024 and is expected to reach US$ 32.83 billion by 2032, growing at a CAGR of 7.9% during the forecast period 2025-2032.

Antipsychotic medications are an important class of psychiatric drugs prescribed to manage psychosis, which includes symptoms such as delusions, hallucinations, and disorganized thinking. These medications are primarily used to treat conditions like schizophrenia, bipolar disorder, and severe depression.

Antipsychotics can be administered in various forms. The most common method is oral ingestion through tablets or liquid formulations. Additionally, some antipsychotics are available as depot injections, which provide a slow-release, long-acting treatment option given every few weeks.

Antipsychotics are effective in alleviating psychotic symptoms and stabilizing mood and help individuals manage their symptoms more effectively, allowing for improved functioning in daily life. The ongoing development of these medications continues to enhance their efficacy and safety profiles, making them a vital component of modern psychiatric care. For instance,

Market Dynamics: Drivers & Restraints

Introduction of innovative antipsychotic drugs

The introduction of innovative antipsychotic drugs is expected to significantly propel the antipsychotic drugs market due to several compelling reasons. Companies are introducing innovative solutions with the ability to treat multiple mental health disorders. For instance, in April 2023, Teva and MedinCell announced FDA approval of UZEDY (risperidone) extended-release injectable suspension, a long-acting subcutaneous atypical antipsychotic injection, for the treatment of schizophrenia in adults. Advanced medications, particularly second and third-generation antipsychotics, are designed with enhanced tolerability, which is crucial for ensuring patient adherence to treatment regimens and consequently increasing the overall demand for these drugs.

Additionally, advancements in pharmaceutical research and development have led to innovative formulations and delivery methods, such as long-acting injectables that provide sustained therapeutic effects while reducing the frequency of dosing. Such innovations not only improve patient compliance but also expand treatment options for complex mental health disorders. For instance, in September 2024, Bristol Myers Squibb received the U.S. Food and Drug Administration (FDA) approval for COBENFY (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults. COBENFY represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating schizophrenia by selectively targeting M 1 and M 4 receptors in the brain without blocking D2 receptors.

Furthermore, the growing global awareness of mental health issues has accelerated the demand for effective antipsychotic treatments, as more individuals seek help for conditions like schizophrenia and bipolar disorder. As the market evolves, the emergence of targeted therapies that focus on specific neurotransmitter systems is also anticipated to attract significant interest from both clinicians and patients, reinforcing the market's growth trajectory.

Lack of awareness of mental health conditions

The lack of awareness regarding mental health conditions is anticipated to significantly impede the growth of the antipsychotic drugs market. Many individuals suffering from psychiatric disorders, such as schizophrenia and bipolar disorder, often do not recognize their symptoms or understand the critical importance of seeking treatment. This gap in awareness can lead to underdiagnosis and undertreatment, resulting in a smaller patient population that requires antipsychotic therapies. Consequently, pharmaceutical companies may struggle to expand their market reach and drive sales effectively.

Segment Analysis

The global antipsychotic drugs market is segmented based on drug type, indication, route of administration, distribution channel, end-user, and region.

Type:

Second-generation antipsychotic drugs segment is expected to dominate the global antipsychotic drugs market share

The second-generation antipsychotic drugs (SGAs) segment is poised to maintain its dominant position in the antipsychotic drugs market, primarily due to their enhanced safety profiles and greater efficacy compared to first-generation antipsychotics (FGAs). Second-generation antipsychotics (SGAs) are a newer class of antipsychotic medications used to treat schizophrenia, bipolar disorder, and related psychiatric conditions

The ongoing product launches and advancements in drug development are expected to further propel the growth of SGAs, with a notable increase in long-acting injectable formulations that improve patient adherence and treatment outcomes. For instance, in June 2021, Alkermes plc received the U.S. Food and Drug Administration (FDA) approval for LYBALVI (olanzapine and samidorphan) for the treatment of adults with schizophrenia and the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate.

Thus, the above factors are expected to show a promising dominance of SGAs in the antipsychotic market in the future, supported by a shift towards innovative treatment options that prioritize both efficacy and safety for patients.

Geographical Analysis

North America is expected to hold a significant position in the global antipsychotic drugs market share

North America is expected to maintain a dominant position in the global antipsychotic drugs market. This dominance is driven by several key factors, including a high prevalence of psychiatric disorders such as schizophrenia and bipolar disorder, which affect millions of people in the region. For instance, according to the report by the National Alliance on Mental Illness (NAMI) in 2022, it indicates that an estimated 7 million adults in the U.S. live with bipolar disorder alone, highlighting the significant demand for effective antipsychotic treatments.

According to the National Institute of Mental Health, it is estimated that more than one in five U.S. adults live with a mental illness (59.3 million in 2022.

North America has a well-established healthcare infrastructure and a strong presence of leading biopharmaceutical companies that are continuously innovating and launching new products. For instance, in April 2024, Vanda Pharmaceuticals Inc. received the U.S. Food and Drug Administration (FDA) approval for Fanapt (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Fanapt is an atypical antipsychotic agent that has been used for the acute treatment of patients with schizophrenia.

North America's healthcare system supports extensive research and development initiatives aimed at creating safer and more effective antipsychotics, including long-acting injectable formulations that improve patient adherence to treatment.

Asia Pacific is growing at the fastest pace in the global antipsychotic drugs market

The Asia Pacific region is experiencing the fastest growth in the antipsychotic drugs market, driven by several key factors. One of the primary contributors is the high prevalence of mental health disorders, with millions affected by conditions such as depression and schizophrenia. For instance, WHO estimates that 54 million people in China suffer from depression, and about 41 million suffer from anxiety disorders. This highlights the urgent need for effective treatment options. Additionally, mental health issues are prevalent across the region, with studies showing that anywhere from 4% to 20% of adults in various countries experience diagnosable mental illnesses annually.

Competitive Landscape

The major global players in the antipsychotic drugs market include Dr. Reddy's Laboratories Ltd., Otsuka Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Alkermes, Eli Lilly and Company, Bristol-Myers Squibb Company, Sumitomo Pharma Co., Ltd. and Pfizer Inc. among others.

Key Developments

• In December 2024, Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on central nervous system disorders, submitted a supplemental New Drug Application to the FDA seeking approval for Caplyta (lumateperone) as an additional treatment for Major Depressive Disorder (MDD) in adults.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Antipsychotic Drugs market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Type
• 3.2. Snippet by Indication
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Introduction of innovative antipsychotic drugs
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of awareness of mental health conditions
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Drug Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 6.1.2. Market Attractiveness Index, By Drug Type
• 6.2. First Generation Antipsychotics*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Risperidone
  • 6.2.4. Quetiapine
  • 6.2.5. Olanzapine
  • 6.2.6. Ziprasidone
  • 6.2.7. Paliperidone
  • 6.2.8. Clozapine
  • 6.2.9. Others
• 6.3. Second Generation Antipsychotics
  • 6.3.1. Chlorpromazine
  • 6.3.2. Flupenthixol
  • 6.3.3. Afluphenazine
  • 6.3.4. Haloperidol
  • 6.3.5. Loxapine
  • 6.3.6. Perphenazine
  • 6.3.7. Pimozide
  • 6.3.8. Trifluoperazine
  • 6.3.9. Others
• 6.4. Third Generation Antipsychotics
  • 6.4.1. Aripiprazole

7. By Indication

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 7.1.2. Market Attractiveness Index, By Indication
• 7.2. Schizophrenia*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Dementia
• 7.4. Bipolar disorder
• 7.5. Depression
• 7.6. Others

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Oral*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Parenteral

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Dr. Reddy's Laboratories Ltd.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Otsuka Pharmaceutical Co., Ltd.
• 12.3. Johnson & Johnson Services, Inc.
• 12.4. Teva Pharmaceutical Industries Ltd.
• 12.5. AbbVie Inc.
• 12.6. Alkermes
• 12.7. Eli Lilly and Company
• 12.8. Bristol-Myers Squibb Company
• 12.9. Sumitomo Pharma Co., Ltd.
• 12.10. Pfizer Inc.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us